Fig. 2.
CpG 2006 ODN is more effective when administration is initiated before AML challenge.
B6 mice (n = 10 per group) were treated with weekly CpG 2006 ODN initiated as indicated, relative to C1498 (2 × 105cells/mouse) infusion. CpG ODN-treated recipients survived significantly (P < .003) longer than nontreated controls, regardless of the schedule used. Mice receiving CpG 2006 beginning on day −2 survived significantly (P < .001) longer than all other groups; those that received CpG 2006 beginning on day 0 survived significantly (P < .05) longer than all groups except the day −2 group.